Literature DB >> 6206970

Interferon production by cultured peripheral leucocytes of MS patients.

G Vervliet, H Carton, E Meulepas, A Billiau.   

Abstract

Peripheral blood leucocytes from multiple sclerosis (MS) patients and from normal individuals were tested for their interferon (IFN) producing capacity after stimulation in vitro with various lectins and viruses. The lectins, Con A, PHA and PWM, induced IFN-gamma. In a kinetic study, the response to Con A revealed itself as an all or none event: the number of responding cultures increased with increasing mitogen dose, but the IFN yield in responding cultures did not differ significantly between dose levels. Thus, any patient or donor could easily be rated as a responder or non-responder. About 1/2 of the MS patients were found to be non-responders if Con A or PHA were used as stimuli. Ninety per cent of the normal donors on the other hand were responders. With PWM as a stimulus 100% of both the MS patients and normal donor groups were found to be responders. Also, with PWM very small doses were sufficient to obtain a 100% response rate among tested cultures, and IFN production persisted for 5 days, while with Con A or PHA it was arrested after 2-3 days. The results indicate that the MS associated lesion is not the absence of functional impairment of all IFN-gamma producing cells, but in only a fraction of them or in an accessory cell population required for the response to Con A and PHA but not to PWM. Newcastle disease virus (NDV) and vesicular stomatitis virus (VSV) both induced IFN-alpha. With NDV as the inducer response rates were 100% and yields were high irrespective of whether the cells were derived from patients or control donors. In contrast, with VSV as the inducer lower response rates were found in cultures from MS patients than in those from controls.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206970      PMCID: PMC1576981     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

1.  Immune interferon induction by T-cell mitogens involves different T-cell subpopulations.

Authors:  D L Archer; B G Smith; J T Ulrich; H M Johnson
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

2.  Interferons and the immune system.

Authors:  B R Bloom
Journal:  Nature       Date:  1980-04-17       Impact factor: 49.962

3.  Interferon responses of leukocytes in multiple sclerosis.

Authors:  P A Neighbour; A E Miller; B R Bloom
Journal:  Neurology       Date:  1981-05       Impact factor: 9.910

4.  Natural killing activity and interferon production in multiple sclerosis.

Authors:  H Zander; J Abb; P Kaudewitz; G Riethmüller
Journal:  Lancet       Date:  1982-01-30       Impact factor: 79.321

5.  Criteria for the clinical diagnosis of multiple sclerosis.

Authors:  A S Rose; G W Ellison; L W Myers; W W Tourtellotte
Journal:  Neurology       Date:  1976-06       Impact factor: 9.910

6.  Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens.

Authors:  G Janossy; M F Greaves
Journal:  Clin Exp Immunol       Date:  1971-10       Impact factor: 4.330

7.  Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.

Authors:  D Santoli; W Hall; L Kastrukoff; R P Lisak; B Perussia; G Trinchieri; H Koprowski
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

8.  Cell-mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells.

Authors:  D Santoli; G Trinchieri; H Koprowski
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

9.  PPD-, PWM-, and PHA-induced interferon in stable multiple sclerosis: association with HLA-Dw2 antigen and clinical variables.

Authors:  R Salonen; J Ilonen; M Reunanen; J Nikoskelainen; A Salmi
Journal:  Ann Neurol       Date:  1982-03       Impact factor: 10.422

10.  Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients.

Authors:  G Vervliet; H Claeys; H Van Haver; H Carton; C Vermylen; E Meulepas; A Billiau
Journal:  J Neurol Sci       Date:  1983-07       Impact factor: 3.181

View more
  5 in total

1.  Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

Authors:  S Inogés; J Merino; E Bandrés; P De Castro; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 2.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

3.  In vitro correction of the interleukin-2 and interferon-gamma defect in multiple sclerosis.

Authors:  G Vervliet; L Schandené
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

4.  Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases.

Authors:  G Vervliet; H Carton; A Billiau
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

5.  Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.

Authors:  E Braakman; A van Tunen; A Meager; C J Lucas
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.